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Abstract
Objective: Several studies have reported upward incidence trends of papillary thyroid cancer. It is unclear whether
these trends reﬂect a real risk increase, by some attributed to iodine supplementation, or an artiﬁcial one, due to
increased diagnostic activity or changed histological criteria. This study examines if these artiﬁcial factors explain
the increased papillary thyroid cancer incidence in the Swiss canton of Geneva.
Methods: All thyroid carcinomas (n¼ 436) recorded between 1970 and 1998 at the Geneva Cancer Registry were
considered. European age-adjusted incidence trends were estimated using linear regression analysis. For papillary
cancers we evaluated diagnostic modalities and way of presentation (in particular microcarcinoma <1 cm or silent
carcinoma). In addition, we reviewed the histological slides of follicular carcinomas.
Results: Papillary thyroid cancer incidence increased signiﬁcantly from 0.7 to 1.8/100,000 for men and from 3.1 to
4.3/100,000 for women between 1970–74 and 1995–98. The proportion of microcarcinomas and silent carcinomas
increased from 17% to 24% between 1970–79 and 1990–98. At histological review, follicular cancers were more
often reclassiﬁed as papillary cancer for cases diagnosed between 1970 and 1979 than for cases diagnosed between
1990 and 1998 (45% vs 25%, p¼ n.s.).
Conclusions: The increasing papillary thyroid cancer incidence seems mainly due to changes in histological
diagnostic criteria and, to a lesser extent, to increased diagnostic activity. If conﬁrmed, the results of this study
indicate that fears of increasing incidence rates of papillary thyroid cancer should not prevent implementation of
adequate programs of iodine supplementation in the many areas where iodine deﬁciency still prevails.
Introduction
Thyroid cancer is of particular interest in Switzerland as
both incidence and mortality rates are among the
highest in the world [1]. Thyroid cancer includes several
histological subtypes (i.e. papillary, follicular, anaplas-
tic, and medullary) of which the papillary subtype is the
most common one (representing 40–70% of all thyroid
cancers) [2]. Over recent decades upward incidence
trends of papillary thyroid cancer have been reported [3,
4] and in the Swiss canton of Geneva the incidence has
also increased. It is, however, uncertain whether these
trends reﬂect real increasing incidence rates or if the
observed trends are artiﬁcial, i.e. caused by increased
diagnostic activity or changes in histological criteria.
Development and improvement of diagnostic modal-
ities – such as cytology, ultrasound, and scintigraphy –
permit easier diagnosis of thyroid nodules. The advent
of these minimally invasive techniques might have
resulted in increased diagnostic activity and, conse-
quently, in a growing diagnosis of small and/or asymp-
tomatic papillary cancers [5].
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In addition, the diagnostic criteria for the histological
classiﬁcation of thyroid tumors have been subject to
changes over recent decades. According to the 1974
World Health Organization (WHO) classiﬁcation, folli-
cular cancer was deﬁned by a malignant epithelial tumor
with architecture and cells similar to those normally
found in an adult thyroid gland. Papillary cancer was
deﬁned as a malignant epithelial tumor with papillary
structures, of which the nuclei may have a ground-glass
appearance [6]. In 1988, new WHO guidelines were
implemented, recommending lesions without the pres-
ence of papillae but with typical cytological features – i.e.
ground-glass nuclei, nuclear grooves, and psammoma
bodies–to be classiﬁed as papillary cancer [7]. These
changes have favored the diagnosis of the papillary
subtype at the expense of the follicular one, and might
explain part of the increased papillary cancer incidence.
This study aims to evaluate whether changes in
diagnostic facilities and histological criteria could ex-
plain the observed increased incidence of papillary
thyroid cancer in Geneva. To evaluate whether the
changed diagnostic facilities increased papillary thyroid
cancer incidence we hypothesized that the proportion
of microcarcinomas and/or silent carcinomas had
increased over time. To evaluate whether changed
diagnostic criteria explained the increased papillary
thyroid cancer incidence, we hypothesized that many
of the tumors diagnosed as follicular cancer before the
change in criteria would today be diagnosed as papillary
cancer.
Materials and methods
Data were derived from the Geneva Cancer Registry
data set, which includes information on all cancers
occurring in the resident population of the canton,
approximately 400,000 inhabitants. The registry collects
information from various sources and is considered very
accurate with a low percentage (<2%) of cases recorded
from death certiﬁcates only [8]. The data collection is
based on a voluntary agreement between the recording
medical institutions of the canton of Geneva and the
registry. Data are abstracted systematically from all
histological laboratories and public hospitals by trained
registrars. These tumor registrars have access to all
medical ﬁles in the public hospitals and they actively
retrieve the required information. Private practitioners
regularly receive inquiry forms to secure missing clinical
and therapeutic data. Death certiﬁcates are consulted
systematically.
Recorded data include: sociodemographic details of
patients (age, gender, nationality, place of birth), diag-
nostic circumstances (consultation following symptoms
in relation to the tumor, screening/check-up, fortuitous
discovery, autopsy, death certiﬁcate), modalities of
diagnostic assessment (clinical status, imaging, cytology,
biopsy, surgery), tumor characteristics (including histo-
logical type and diﬀerentiation coded according to the
International Classiﬁcation of Diseases for Oncology,
ICD-O) [9], stage of disease at diagnosis, treatment
during the ﬁrst six months after diagnosis, survival
status, and second primary tumor occurrence. Tumor
recurrences are not systematically recorded.
In this study we included all incident cases of
histologically conﬁrmed thyroid cancer (ICD-O code:
193) diagnosed between 1970 and 1998 (n¼ 436, 107
among men and 329 among women). Histological
subtypes were classiﬁed into papillary carcinoma, fol-
licular carcinoma, and other (including anaplastic car-
cinoma and medullary carcinoma). Trends in incidence
rates (European standard) were estimated for both
genders and histological subtypes by means of linear
regression analysis based on the maximum-likelihood
method with generalized log-linear modeling [10].
To test our ﬁrst hypothesis (i.e. if the increased
papillary thyroid cancer incidence were due to increased
diagnostic activity, the proportion of microcarcinomas
and/or silent carcinomas would have increased over
time), we opened the clinical ﬁles of patients diagnosed
with papillary thyroid cancer and retrieved additional
information on method of diagnosis (especially on the
use of cytology) and on the way of presentation at
diagnosis. We classiﬁed papillary cancers into the
following categories: (1) microcarcinoma, i.e. cancers
with a tumor diameter 1 cm; (2) silent carcinomas, i.e.
other tumors with no apparent symptoms (i.e. fortui-
tously discovered, detected at autopsy); and (3) clinical
cancer, tumors presenting with symptoms compatible
with thyroid pathology.
To test our second hypothesis (i.e. if the increased
papillary cancer incidence were caused by changed
diagnostic criteria, many of the tumors diagnosed as
follicular cancer before the change in criteria would
today be diagnosed as papillary cancer), we performed a
histological review of thyroid cancers originally diag-
nosed as follicular cancer between 1970 and 1980 (early
period) and between 1990 and 1998 (late period). In the
early period the 1974 WHO criteria were generally used,
and in the late period the 1988 WHO criteria were
applied. The histological review was performed by a
pathologist with extensive experience and special inter-
est in thyroid pathology. This pathologist assesses more
than 50% of all thyroid lesions that are operated in the
Geneva University Hospital and is the consultant for
thyroid pathology for the surgeons. The original slides
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of the tumors were obtained. The revision was executed
following the instructions of the Armed Forces of
Pathology (AFIP) Tumors of the Thyroid gland [11],
which are very similar to the 1988 WHO guidelines.
We calculated the proportions of reclassiﬁcation of
follicular cancer (with 95% conﬁdence intervals). Final-
ly, we estimated the incidence rates according to
histological subtype, adjusting for the level of reclassi-
ﬁcation.
Results
Trends of thyroid cancer by histological subtype are
presented in Figure 1. The overall incidence of thyroid
cancer did not change signiﬁcantly over the past three
decades (linear tri-annual trend 0.99, 95% CI 0.96–1.03)
and was the same for men (0.95, 95% CI 0.88–1.01) and
women (1.01, 95% CI 0.97–1.05). The incidence rate of
papillary cancer increased signiﬁcantly over time (linear
tri-annual trend 1.07, 95% CI 1.02–1.13), and was
comparable for men (1.14, 95% CI 1.03–1.26) and
women (1.06, 95% CI 1.01–1.12). The incidence of
follicular cancer decreased (linear tri-annual trend 0.87,
95% CI 0.81–0.94). Among men there was a sharp
decrease (linear trend 0.71, 95% CI 0.60–0.82), but
among women the decrease was not signiﬁcant (linear
trend 0.96, 95% CI 0.87–1.05). The overall incidence of
other histological subtypes also decreased signiﬁcantly
(linear tri-annual trend 0.92, 95% CI 0.86–0.99) and the
trend was similar for men (linear trend 0.88, 95% CI
0.76–1.02) and women (linear tri-annual trend 0.94,
95% CI 0.86–1.02).
As expected, the use of cytology increased consider-
ably. Between 1970 and 1974 none of the papillary
thyroid cancers was diagnosed by means of cytology,
whereas between 1995 and 1998 almost 50% of the
papillary cancers were diagnosed cytologically (data not
shown). However, the proportion of silent carcinomas
and microcarcinomas increased only slightly from 17%
in 1970–79 to 24% in 1990–98 (Figure 2).
Table 1 shows the results of the histological review of
the thyroid tumors originally diagnosed as follicular
cancer. Histological blocks were retrieved for 33 (69%)
of the 48 patients diagnosed between 1970 and 1980 and
16 of the 20 (80%) patients diagnosed between 1990 and
1998. Lesions diagnosed as follicular cancer in the early
period were reclassiﬁed as follows: 15 (45%) papillary
carcinoma, six (18%) poorly diﬀerentiated/anaplastic
carcinoma, and three (9%) as benign adenoma. In only
nine (27%) patients was the diagnosis follicular cancer
maintained. In the late period a substantially lower
proportion of follicular cancers was re-diagnosed as
papillary cancer (n¼ 4, 25%). In this period the initial
diagnosis of follicular cancer was conﬁrmed in 11 (69%)
patients.
We used the proportions of reclassiﬁcation to recal-
culate the crude incidence rates according to histological
subtype (Table 2). The observed diﬀerence in papillary
thyroid cancer incidence between the early and the late
period was 1.18/100,000. After correction this diﬀerence
was reduced by 36% to 0.75/100,000.
Fig. 1. Mean annual incidence rates (age standardized to European
population) by histological subtype for men (panel a) and women
(panel b).
Fig. 2. Proportion (and 95% conﬁdence intervals) of papillary thyroid
cancers presenting as microcarcinomas (£1 cm) or silent carcinoma
(other tumor with no apparent symptoms of thyroid pathology) per
period (both sexes together).
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Discussion
Increasing rates of papillary thyroid cancer incidence is
a well-documented phenomenon in industrialized coun-
tries. Papillary thyroid cancers are in general well-
diﬀerentiated tumors with an excellent prognosis [1].
Mortality rates of thyroid cancer have decreased in
Switzerland over recent decades (world standardized
mortality rates were 1.4/100,000 for men and 1.6/
100,000 for women during the period 1955–64 and went
to 0.7 and 1.0 respectively for the period 1985–89) [12].
In the USA the increasing papillary thyroid cancer
incidence has been attributed to the wide use of
radiation treatment for benign childhood head and neck
conditions between 1930 and 1960 [1]. However, in-
creasing incidences were also observed in the Nordic
countries where, as in Switzerland, radiation therapy for
benign conditions was used infrequently.
Iodine, both as deﬁcit and excess, has also been
suggested to play a role in the etiology of respectively
follicular and papillary thyroid cancer [1]. Switzerland is
an iodine-deﬁcient country, and goiter and cretinism
related to this deﬁcit were especially frequent in moun-
tainous rural areas [2]. In an attempt to prevent these
diseases the Swiss authorities implemented several
prophylactic programs, including the introduction of
iodine-enriched salt since 1922 [13]. In previous studies
for other ex-endemic goiter regions where iodine was
supplemented, similar increasing papillary cancer inci-
dence rates were reported [14, 15]. It has therefore been
suggested that the increased papillary cancer incidence is
caused by increased iodine intake by the population.
According to this theory iodine deﬁciency enhances the
transition from papillary carcinoma (the early carcino-
ma of the thyroid gland) toward less diﬀerentiated, more
aggressive types. Iodine implementation might prevent
this transition [3]. Data from Sweden did not suggest
any enhancing eﬀect of iodization on papillary carcino-
ma, as increases in papillary thyroid cancer incidence
were similar in iodine-deﬁcient and iodine-suﬃcient
areas [16].
The present study indicates that the sharp increase in
papillary thyroid cancer incidence between 1970 and
1998 in Geneva can be partly explained by changes in
histological WHO criteria in 1988. The slight increase in
papillary thyroid cancer that was observed before 1985
may be explained by an increased use of minimally
invasive techniques, in particular ﬁne-needle cytology.
Although the use of cytology has increased tremen-
dously, this did not signiﬁcantly increase the proportion
of silent papillary cancers or microcarcinomas. Probably
cytology has been increasingly used as a ﬁrst step in the
assessment of symptomatic thyroid abnormalities (i.e.
nodules). We nevertheless feel that the nonsigniﬁcant
increase in the proportion of silent carcinomas should be
interpreted cautiously. Nowadays, many frequent symp-
toms among women (i.e. disorders of menstruation,
tiredness, nervousness, etc.) often lead to a search for
thyroid abnormalities which might increase the number
of silent carcinomas detected [17, 18].
In this study 45% of the lesions diagnosed as follicular
cancer between 1970 and 1980 were reclassiﬁed as
papillary cancer (compared to 25% between 1990 and
1998). In 1988, the World Health Organization imple-
mented new diagnostic criteria for the histological
classiﬁcation of thyroid tumors [7]. Before the change
in criteria the predominance of a papillary architectural
component was mandatory to classify a lesion as
papillary cancer. After the changes, lesions without the
presence of papillae but with typical cytological features,
Table 1. Results of histological review: (re)classiﬁcation of thyroid carcinomas originally diagnosed as follicular carcinoma (both sexes together)
‘‘Follicular’’ carcinoma (re)classiﬁed as 1970–80 (n = 33) 1990–98 (n = 16)
No. Percentage (95% CI) No. Percentage (95% CI)
Follicular carcinoma 9 27%, (13–46) 11 69%, (41–89)
Papillary carcinoma 15 45%, (28–64) 4 25%, (7–52)
Poorly diﬀerentiated/anaplastic carcinoma 6 18%, (7–36) 1 6%, (0–30)
Benign adenoma 3 9%, (2–24) 0 0%, (0–21)
Table 2. Observed and corrected incidence rates (1,100,000) of thyroid
cancer according to histological subtype (both sexes together)
1970–80 1990–98
Observed Correcteda Observed Correctedb
Papillary cancer 1.88 2.46 3.06 3.21
Follicular cancer 1.29 0.35 0.62 0.43
Other cancers 1.15 1.39 0.82 0.86
Total 4.32 4.20c 4.50 4.50
a 45% of follicular cancers reclassiﬁed as papillary cancer, 18%
reclassiﬁed as other cancer, 27% remained follicular cancer.
b 25% of follicular cancers reclassiﬁed as papillary cancer, 6%
reclassiﬁed as other cancer, 69% remained follicular cancer.
c 9% of thyroid cancers diagnosed as follicular carcinoma between
1970 and 1980 were reclassiﬁed as benign.
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i.e. ground-glass nuclei, nuclear grooves, and psammo-
ma bodies, were recommended to be classiﬁed as
papillary cancer. Accordingly, the deﬁnition of papillary
cancer was widened and lesions that were previously
(correctly) classiﬁed as follicular cancer are nowadays
being classiﬁed as papillary cancer [2].
Our observations are in accordance with the ﬁndings
of previous investigators who also reported high levels
of reclassiﬁcation among tumors diagnosed as follicular
thyroid cancer [4, 19]. This study additionally demon-
strates a strong variation in level of reclassiﬁcation over
time.
Previous studies demonstrated that the diagnosis
‘‘papillary thyroid cancer’’ is maintained in the great
majority of cases (93–98%) [4, 19]. We therefore
assumed that reclassiﬁcation of tumors initially diag-
nosed as papillary thyroid cancer does not have an
impact on papillary cancer incidence, and limited the
histological review to follicular thyroid cancer. Despite
thorough research we did not ﬁnd 19 histological blocks.
This could introduce a bias if the missing cases presented
a diﬀerent histological proﬁle than the reviewed cases.
However, no diﬀerences were found in terms of socio-
demographic data, method of diagnosis, or tumor
characteristics as recorded by the cancer registry.
We realize that the number of cases in our histological
review is too low to draw any deﬁnite conclusions. Also,
we were not able to address another consequence of the
changed diagnostic criteria in this study. Some benign-
appearing lesions, formerly diagnosed as benign adeno-
ma, are nowadays classiﬁed as papillary cancer [2]. As
the Geneva Cancer Registry registers only malignant
lesions, we were not able to evaluate whether this
phenomenon attributed to the increased papillary thy-
roid cancer incidence. Future research is needed to
elucidate this speciﬁc question.
This study evaluates to what extent changes in
diagnostic facilities and histological criteria could ex-
plain the observed increased incidence of papillary
thyroid cancer in a high-risk area of thyroid cancer.
We conclude that the changes in histological criteria
favoring the classiﬁcation of the papillary type may
explain an important fraction of the increase. If con-
ﬁrmed, the present ﬁndings are of substantial impor-
tance from a public health viewpoint. Fears of increases
in the incidence of papillary carcinoma should not
hamper the implementation of adequate programs of
iodine supplementation in many European countries
(e.g. France, Belgium, Italy, etc.) where iodine deﬁciency
still prevails [20, 21].
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